!

"#$%
'()*+,+-'./.0(
!."+*!(*"
DSM-5 is a registered trademark, and all content, whether in final or
proposed form, is protected by copyright held by the APA. All rights are
reserved, and written permission is required from the APA for use in any way,
commercial or noncommercial. Permission is not granted for use of the
DSM-5 trademark.
!"#$%$&'
!"#$ !&'()*+,-.!/,0'-.0 1.2)/)*/,3
!&'()*+,-.!/,0'-.0 !#'4*/14. .*/5453/.)
!#'4*/14. .*/5453/.) !67&
!67&
!"'")*$+ ,')"-*$. /$-0%/"%
!849:./;.2<) *=1. !"#$
!>+)-'4+2 !&'()*+,-.!/,0'-.0 1.2)/)*/,3
!"#$ !67&
?@> 102)$*$3" !$-0%/"% 456
?.+0 *2+';+ !#/40 ,.'25-53,/*/A. 0/)520.2 #$@
B/-C<) 0/).+). !B5)*!-5,-'))/5,+4 0/)520.2
$2.'*9D.40*!E+C5( 0/).+).
7*:.2
!6789: 15;49<9:= !965>!=>6
Beliiium
Neuiocognitive uisoiuei
-Najoi
-Nilu
!"#$%
'()*+,+-'./.0( !."+*!(*"
F/)*'2(+,-. 5D -5,)-/5'),.))
$53,/*/A. -:+,3. 52 1.2-.1*'+4 0/)*'2(+,-.
GA54A.0 5A.2 ):52* 1.2/50
! uistuibance in attention anu awaieness
!"#$%
!(1.*.)#
H#.;52= /;1+/2;.,* 14')
I81:+)/+ J4+,3'+3.K
I812+L/+ J-+22= 5'* ;5*52 +-*/A/*/.)K
I83,5)/+ J2.-53,/9.M/0.,*/D= 5(N.-*)K
IGL.-'*/A. D',-*/5,/,3 J14+,,/,3O
523+,/9/,3O ).P'.,-/,3O +()*2+-*/5,K
!"#$.0
!(#('/.2
!=7=4<9,
QR 849:./;.2<) *=1.
SR >+)-'4+2
TR "#$
!?@>
!?.+0 *2+';+
!B+2C/,)5,<) 0/).+).
!B/-C<) 0/).+).
!$2.'*9D.40*!E+C5( 0/).+).
UR &'()*+,-.!/,0'-.0 1.2)/)*/,3
VR #'4*/14. .*/5453/.)
456
!"#$.03 !(#('/.2
% ")4/56("
Alzheimei's uisease
Fiontotempoial lobai uegeneiation
Lewy bouy uisease
vasculai uisease
Tiaumatic biain injuiy
Substancemeuication-inuuceu
BIv infection
Piion uisease
Paikinson's uisease
Buntington's uisease
Bue to anothei meuical conuition
Nultiple etiologies
!"#$%3 '()*+,+-'./.0( !."+*!(*
78 ")4/56("
significant cognitive uecline in >1 uomain, piefeiably on stanuaiuizeu
neuiopsychological testing
-cognitive uomains:
complex attention
executive function
leainingmemoiy
language
peiceptual-motoi
social cognition
inteifeie with inuepenuence
!"#$%3 #29+* '()*+,+-'./.0(
!."+*!(*
mouest cognitive uecline in >1
uomain, piefeiably on stanuaiuizeu
neuiopsychological testing
uo not inteifeie with inuepenuence
!"#$%3 #.1! '()*+,+-'./.0(
!."+*!(*
#:;<=
-Associateu meuical coue, except
vasculai
Substancemeuication-inuuceu
-Piobable vs possible, except
Tiaumatic biain injuiy
Substancemeuication-inuuceu
BIv
Piion
Buntington's
-Behavioial uistuibance
-Seveiity
Nilu (IABLs)
Noueiate (ABLs)
Seveie (fully uepenuent)
!"#$%3 '()*+,+-'./.0(
!."+*!(*
o 6=<>:>?@ vs 6<AAB>?@
uenetic testing
oi
Cleai eviuence of uecline
Piogiessive, giauual uecline
No mixeu etiology
#29+* '()*+,+-'./.0( !."+*!(*
!)( /+ 21CD(.#(*E" !."(2"(
o 6=<>:>?@ vs 6<AAB>?@
uenetic testing Cleai eviuence of uecline

Piogiessive, giauual uecline

No mixeu etiology
MILD NEUROCOGNITIVE DISORDER
DUE TO ALZHEIMERS DISEASE
4@F:GB<=:? G:=B:HI
>S
behavioial uisinhibition
apathyineitia
loss of sympathyempathy
peiseveiative, steieotypeu oi compulsiveiitualistic behavioi
hypeioialityuietaiy changes
1:HJK:J@ G:=B:HI
6=<>:>?@ vs 6<AAB>?@
uenetic testing histoiy anu clinical featuies only
oi
Neuioimaging
L*+'/+/(#6+*21
'()*+,+-'./.0( !."+*!(*
,<=@ M@:IK=@A
-fluctuating cognition, attention, aleitness
-iecuiient visual hallucinations
-spontaneous paikinsonism
"KJJ@AIBG@ NB:JH<AIBO M@:IK=@A
-iapiu eye movement sleep behavioi uisoiuei
-seveie neuioleptic sensitivity
6=<>:>?@ vs 6<AAB>?@
2 coies oi 1 coie + >1 suggestive only 1 coie oi >1
suggestive
'()*+,+-'./.0( !."+*!(* P./D
1(P5 4+!.("
onset temporally related to a cerebrovascular event
prominent decline in complex attention
Probable vs Possible
Neuroimaging
or
Temporally linked to documented event
or
Clinical and genetic evidence
02",)12* '()*+,+-'./.0(
!."+*!(*
No eviuence of mixeu etiology
Paikinson's uisease cleaily pieceues
6=<>:>?@ vs 6<AAB>?@
Both 1 of 2
'()*+,+-'./.0( !."+*!(* !)(
/+ 62*Q.'"+'E" !."(2"(
*tiaumatic biain injuiy
>1
-loss of consciousness
-posttiaumatic amnesia
-uisoiientationconfusion
-neuiological signs: neuioimaging, onset of seizuie, visual fielu cut,
hemipaiesis.
'()*+,+-'./.0( !."+*!(* !)(
/+ /*2)#2/., 4*2.' .'9)*5
!=7=4<9, ! #:;<= '@K=<O<JHBIBG@ NBA<=N@=
849:./;.2<) *=1. ! Alzheimei's uisease
>+)-'4+2 ! vasculai uisease
"#$
!?@> !BIv infection
!?.+0 *2+';+ ! Tiaumatic biain injuiy
!B+2C/,)5,<) 0/).+). ! Paikinson's uisease
!B/-C<) 0/).+). ! Fiontotempoial lobai uegeneiation
!$2.'*9D.40*!E+C5( 0/).+). !Piion uisease
!7*:.2 ! Lewy bouy uisease
! Buntington's uisease
! Anothei meuical conuition
&'()*+,-. /,0'-.0 1.2)/)*/,3 ! Substancemeuication use
#'4*/14. .*/5453/.) ! multiple etiologies
67& ! unspecifieu
!"#$.0 ! !"#$%
Collapses 0.4/2/';O 0.;.,*/+O +;,.)*/- 0/)520.2
anu 5*:.2 -53,/*/A. 0/)520.2
!@?B=BKR anu H@K=<O<JHBIBG@ NBA<=N@=
")##2*5 7
Neuiocognitive uisoiuei
-1u subtypes
-Najoi: significant uecline, loss of inuepenuence
-Nilu: mouest uecline, pieseiveu inuepenuence
")##2*5 S
Najoi neuiocognitive uisoiuei
-Associateu meuical coue
-Piobable vs possible
-With oi without behavioial uistuibance
-Seveiity: milu, moueiate, seveie
")##2*5 T